Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

Sponsor

Omeros Corporation (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05855083

Collaborator

(none)

Enrollment

Locations

Arm

Anticipated Duration (Months)

1.1

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).

Condition or Disease	Intervention/Treatment	Phase
Thrombotic Microangiopathies Hematopoietic Stem Cell Transplantation	Drug: Biological: narsoplimab	Phase 2

Detailed Description

This is a Phase 2, uncontrolled, single-dosing regimen study in pediatric patients from 28 days to less than 18 years of age with high risk HSCT-TMA. At least 4 patients will be required from each of 3 age cohorts:

28 days to <2 years of age, 2 years to <12 years of age, and 12 years to <18 years of age.

Treatment will be for 8 weeks and patients will be followed for up to 52 weeks.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

18 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Pediatric Patients (28 Days to ≤ 18 Years of Age.) With High-Risk Hematopoietic Stem Cell Transplant Thrombotic Microangiopathy

Anticipated Study Start Date :

May 1, 2023

Anticipated Primary Completion Date :

Dec 1, 2025

Anticipated Study Completion Date :

Dec 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Narsoplimab single arm-treatment Narsoplimab 4 mg/kg	Drug: Biological: narsoplimab Treatment with narsoplimab 4 mg/kg will be administered Other Names: Narsoplimab

Arm

Intervention/Treatment

Experimental: Narsoplimab single arm-treatment

Narsoplimab 4 mg/kg

Drug: Biological: narsoplimab

Treatment with narsoplimab 4 mg/kg will be administered

Other Names:

Narsoplimab

Outcome Measures

Primary Outcome Measures

100-day survival rate following high-risk HSCT-TMA diagnosis. [100 days]
Percentage of patients alive at 100 days following the diagnosis of high-risk HSCT-TMA

Secondary Outcome Measures

Number of participants with treatment-emergent adverse events assessed by CTCAE v5.0 [52 weeks]
Number and percentage of patients with treatment-emergent adverse events will be summarized by MedDRA system organ class and preferred term
Percentage of patients meeting protocol definition of clinical response [52 weeks]
A responder is defined as a patient with HSCT-TMA who demonstrates improvement in laboratory TMA markers (platelet count and LDH) and clinical benefit (either improvement in organ function or reduction in transfusion burden)
52 week survival rate following high-risk HSCT-TMA diagnosis [52 weeks]
Percentage of patients alive at 52 weeks following the diagnosis of high-risk HSCT-TMA
Overall survival following the diagnosis of high-risk HSCT-TMA [52 weeks]
Median overall survival (days) following the diagnosis of high-risk HSCT-TMA by Kaplan-Meier estimate
Pharmacokinetics (PK) of multiple-dose administration of OMS721 [52 weeks]
PK parameters including maximum concentration and minimum (trough) concentration
Presence of anti-drug antibody (ADA) [52 weeks]
Number and percentage of patient with at least one ADA positive sample

Eligibility Criteria

Criteria

Ages Eligible for Study:

28 Days to 17 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age at least 28 days and less than 18 years prior to informed consent (Visit 0).
Have informed consent from at least one parent or legal guardian as required by local law and regulation. Patient informed consent will be required if the patient has reached the local legal age of majority.
Assent from patients as required by local law and regulation.
Have received an allogeneic hematopoietic stem cell transplant for the treatment of benign or malignant disease.
Have a diagnosis of HSCT-TMA defined as meeting both of the following criteria:

Platelet count < 50,000/mL or a decrease in platelet count > 50% from the highest value obtained following transplant.
Evidence of microangiopathic hemolysis (presence of schistocytes, serum lactate dehydrogenase [LDH] > upper limit of normal ([ULN], or haptoglobin < lower limit of normal [LLN])

Have at least one of the following HSCT-TMA high-risk criteria:

HSCT-TMA persistence > 2 weeks following modification of calcineurin inhibitors or sirolimus OR
Have evidence of high-risk HSCT-TMA defined as at least one of the following:
Spot protein/creatinine ratio > 2 mg/mg
Serum creatinine > 1.5 x the creatinine level prior to TMA development
Biopsy-proven gastrointestinal TMA
TMA-related neurological abnormality
Pericardial or pleural effusion without alternative explanation
Pulmonary hypertension without alternative explanation
Have Grade III or Grade IV graft-versus-host disease (GVHD) or, in the opinion of the Investigator, risk for development of Grade III or Grade IV GVHD if immunosuppression were to be modified
Have elevated serum C5b-9 (> 244 ng/mL)

If sexually active and of childbearing potential (for female pediatric patients, defined as starting at onset of menses), must agree to practice a highly effective method of birth control throughout study drug treatment and for at least 12 weeks after the last dose of study drug, such method of birth control defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence (abstinence is acceptable when it is in line with the patient's preferred and usual lifestyle and is defined as complete abstinence of sexual intercourse, not periodic abstinence or withdrawal), or vasectomized partner.
Male patients must be willing to avoid fathering children for at least 12 weeks following the last dose of study medication.

Exclusion Criteria:

All treatments for HSCT-TMA are allowed except eculizumab, ravulizumab, and defibrotide within 3 months prior to informed consent, unless failure of therapy can be documented.

Patients may not be on eculizumab, ravulizumab, or defibrotide for any indication at screening.

Have Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS). Test results obtained within 28 days prior to informed consent may be used.
Have ADAMTS13 activity < 10%. Test results obtained within 28 days prior to informed consent may be used.
Have a severe, uncontrolled systemic bacterial or fungal infection requiring antimicrobial therapy, or a severe uncontrolled viral infection (as determined by the investigator); prophylactic antimicrobial therapy administered as standard of care is allowed.
Have malignant hypertension (blood pressure [BP] > 99th percentile plus 5 mmHg with bilateral hemorrhages or "cotton-wool" exudates on fundoscopic examination).
Due to conditions other than HSCT-TMA, have a poor prognosis with a life expectancy of less than 3 months in the opinion of the Investigator.
If pregnant or lactating.
Have received treatment with an investigational drug or device within 4 weeks of entering study.
Have abnormal liver function tests defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times ULN within 28 days prior to informed consent.
Have a positive test by antigen or polymerase chain reaction (PCR) for human immunodeficiency virus (HIV), if negative within 28 days prior to informed consent, the test does not need to be repeated.
Patient or one or more of the patient's parents or legal guardians are is an employee or an immediate family member of Omeros, the Clinical Research Organization (CRO), an Investigator, or a study staff member.
Have a known hypersensitivity to any constituent of the product.
Presence of any condition that the Investigator believes would put the patient at risk.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Omeros Investigational Site	San Diego	California	United States	92024
2	Omeros Investigational Site	Gainesville	Florida	United States	32608
3	Omeros Investigational Site	Boston	Massachusetts	United States	02215
4	Omeros Investigational Site	Saint Louis	Missouri	United States	63104
5	Omeros Investigational Site	New York	New York	United States	10065
6	Omeros Investigational Site	Valhalla	New York	United States	10595
7	Omeros Investigational Site	Houston	Texas	United States	77030
8	Omeros Investigational Site	Seattle	Washington	United States	98105
9	Omeros Investigational Site	Halle		Germany
10	Omeros Investigational Site	Hanover		Germany
11	Omeros Investigational Site	Budapest		Hungary
12	Omeros Investigational Site	Haifa		Israel
13	Omeros Investigational Site	Jerusalem		Israel
14	Omeros Investigational Site	Ramat Gan		Israel
15	Omeros Investigational Site	Tel Aviv		Israel
16	Omeros Investigational Site	Utrecht		Netherlands
17	Omeros Investigational Site	Pamplona		Spain